Heparin Market Size, Share & Analysis Report, 2022-2030
The global Heparin market size was estimated at USD 7.8 billion in 2021 and is expected to surpass around USD 9.4 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 2.7% during the forecast period 2022 to 2030.
Growth Factors:
The increasing prevalence of conditions such as renal impairment, coronary artery disease, and venous thromboembolism is anticipated to drive the market. According to the CDC in 2022, each year around 900,000 people could be affected in the United States with venous thromboembolism which may result in the death of 10% - 30% of people within one month of diagnosis.
The outbreak of COVID-19 has boosted the market significantly in 2020 and 2021. As per JAMA Journal in 2021, abnormal blood clots are common in COVID-19 patients owing to clot–promoting autoantibodies which lead to deep vein thrombosis and pulmonary embolisms, which creates an opportunity for heparin. As per an article published in the Journal of the American Heart Association (JAHA) in 2021, anticoagulation therapy of low-molecular-weight heparin given in the early stages of disease could better prevent COVID?19–associated coagulopathy and endotheliopathy that lead to a better prognosis in a patient. All the above factors are expected to contribute to market growth.
High demand for anticoagulants is anticipated to boost the overall market. Furthermore, rising health care expenditure and initiatives undertaken by government bodies are some of the key factors anticipated to drive the market growth. The increasing prevalence of chronic diseases such as cardiovascular disorders, deep vein thrombosis, pulmonary embolism, and renal diseases is considered to be one of the major factors driving the overall market.
Lack of exercise, excess smoking and drinking, unhealthy food habits, and changing lifestyles are some major factors that increase the incidence of non-communicable diseases such as coronary artery disease (CAD), hypertension, and diabetes. According to the Korea Biomedical Review, the prevalence of diabetes over 30 years stood at 13.8% in 2020. Diabetic patients have a high probability of blood coagulation which leads to heart disease and kidney complications. The use of heparin for the treatment of such conditions is projected to drive market growth.
The U.S. is experiencing a shortage of heparin in 2022 attributable to a high demand in the region. For instance, in mid-July 2022, Baxter, BBraun, Fresenius Kabi, and Pfizer are experiencing a shortage attributable to high demand and delays in manufacturing. The high demand is a result of escalated hospitalization rates in the nation owing to SARS-CoV-2.
Report Scope of the Heparin Market
|
Report Coverage |
Details |
|
Market Size |
US$ 9.4 Billion by 2030 |
|
Growth Rate |
CAGR of 2.7% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Type, route of administration, application, end-use, source and Region, |
|
Companies Mentioned |
GlaxoSmithKline plc; Pfizer, Inc.; LEO Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; Sandoz (Novartis AG) |
Type Insights
The Low Molecular Weight Heparin (LMWH) segment held the highest market share of 63.9% in 2021 owing to the reliable anticoagulant effect when compared to other forms of heparin such as unfractionated heparin. The use of LMWH in the treatment of COVID-19 patients is expected to further accelerate the demand for the product. Based on an article published on Springer in 2021, the use of prophylactic doses of heparin in COVID-19 patients reduces mortality by 70% in patients with a moderate or mild form of the disease. This is expected to boost the usage of the molecule in patients.
The Ultra-Low Molecular Weight Heparin (ULMWH) segment is expected to witness the fastest growth over the forecast period owing to the commercialization of novel products with enhanced pharmacological effects. The better activity of ULMWH and controllability, along with low bleeding incidence is facilitating the fastest growth rate of ULMWH products.
Application Insights
The coronary artery disease segment dominated the market and accounted for the largest revenue share of 23.6% in 2021 owing to the increasing prevalence of heart-related disorders. The lack of physical activity, high blood pressure, and excess smoking are major factors contributing to the increased incidence of coronary artery disease. The increasing number of hospital stay days post-surgery and bedridden patients with restricted movements creates an opportunity for heparin as they are at high risk of blood clot development.
The venous thromboembolism segment is expected to demonstrate the fastest growth over the forecast period. The rising prevalence of pulmonary embolism can be attributed to the rapidly growing geriatric population and medical comorbidities. Moreover, the growing obese population globally is another factor contributing to the increasing prevalence of these diseases. Obese people are sixfold more likely to develop deep vein thrombosis.
End-use Insights
The outpatient segment dominated the market and accounted for the largest revenue share of 60.9% in 2021. Outpatients have an advantage over others due to the reduction in hospital expenses such as hospital admission costs and other hospitality-related costs. Low cost, increased availability of services, and patient convenience is key factors responsible for the large share of this segment.
The inpatient segment is expected to grow at a lucrative rate over the forecast period due to the improved quality of wound healing equipment and quicker recovery time in the patient. The presence of effective insurance and reimbursement policies increases the footfall of hospitals thereby expected to boost the inpatient service segment.
Source Insights
The porcine segment dominated the market and held the largest revenue share of 90.5% in 2021. The segment is expected to maintain its dominance over the forecast period due to its wide usage in the production of heparin, especially low molecular weight heparins such as enoxaparin. However, Jewish and Muslim people refrain from using porcine-derived products because of their religious beliefs, restraining the adoption of heparin.
The bovine segment is also expected to witness significant growth during the forecast period due to the shortage of porcine heparin due to the limited availability of intestinal mucosa and negative social beliefs about porcine heparin are major factors that boost the growth of this segment. However, the less efficacy of bovine over porcine heparin is expected to diminish the segment growth.
Route Of Administration Insights
The subcutaneous segment dominated the market and accounted for the largest revenue share of 64.9% in 2021 owing to low hospitalization-associated costs, rising demand for home care treatment, and the advantages such as ease in administration are anticipated to propel the market growth. The higher compliance rate of patients for subcutaneous heparin acts as an advantage for the segment.
The intravenous route of administration segment is expected to grow at a lucrative rate over the forecast period. Heparin, especially unfractionated heparin, is administered via the intravenous route. It offers rapid entry into the bloodstream and acts swiftly to prevent blood clots. Drug concentration control in the blood is also easier with the intravenous mode of administration.
Regional Insights
North America dominated the market and accounted for the largest revenue share of in 2021. This is due to the rising cardiovascular disorders and injuries. In addition, increasing healthcare expenditure levels, and growing patient awareness in this region are the factors that can be attributed to the region’s high share. According to CDC in 2022, 659,000 people in the United States die from heart disease each year which is 1 in every 4 deaths and was marked as one of the major causes of death in the country.
In the Asia Pacific, the market is projected to witness the fastest growth rate over the forecast period. The rising geriatric population, large population with chronic disease, and growing economies are some of the primary factors driving the growth. Asia Pacific is also the largest supplier of crude heparin and its API. This gives an advantage to local firms, such as Pharmax Lifesciences. Local companies are producing cost-effective generic medicines of patent-expired drugs.
Some of the prominent players in the Heparin Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Heparin market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Heparin Market Study:
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 Nova one advisor’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Competitive Insights
Chapter 3 Heparin Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increasing prevalence of chronic diseases
3.2.1.2 Growing demand for whole blood and blood components transfusion
3.2.1.3 Increasing geriatric population
3.2.1.4 High usage of plasma in the pharmaceutical industry
3.2.2 Market restraint analysis
3.2.2.1 Risk of blood-transmitted diseases and an increasing number of blood substitutes
3.2.2.2 Emerging oral anticoagulants
3.3 Penetration & Growth Prospect Mapping
3.4 Heparin: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
Chapter 4 Heparin Market Segment Analysis, By Type, 2017 - 2030
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Heparin Market, by Type, 2017 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
4.5.1 Low Molecular Weight Heparin (LMWH)
4.5.1.1 Low molecular weight heparin market, 2017 - 2030
4.5.2 Ultra-Low Molecular Weight Heparin (ULMWH)
4.5.2.1 Ultra-Low molecular weight heparin market, 2017 - 2030
4.5.3 Unfractionated Heparin
4.5.3.1 Unfractionated heparin market, 2017 - 2030
Chapter 5 Heparin Market Segment Analysis, By Route of Administration, 2017 - 2030
5.1 Definition and Scope
5.2 Route of Administration Market Share Analysis, 2021 & 2030
5.3 Segment Dashboard
5.4 Global Heparin Market, by Route of Administration, 2017 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
5.5.1 Intravenous
5.5.1.1 Intravenous market, 2017 - 2030
5.5.2 Subcutaneous
5.5.2.1 Subcutaneous market, 2017 - 2030
Chapter 6 Heparin Market Segment Analysis, By Application, 2017 - 2030
6.1 Definition and Scope
6.2 Application Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Heparin Market, by Application, 2017 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
6.5.1 Venous Thromboembolism
6.5.1.1 Venous thromboembolism market, 2017 - 2030
6.5.2 Coronary Artery Disease
6.5.2.1 Coronary artery disease market, 2017 - 2030
6.5.3 Renal Impairment
6.5.3.1 Renal impairment market, 2017 - 2030
6.5.4 Atrial Fibrillation
6.5.4.1 Atrial fibrillation market, 2017 - 2030
6.5.5 Others
6.5.5.1 Others market, 2017 - 2030
Chapter 7 Heparin Market Segment Analysis, By End-use, 2017 - 2030
7.1 Definition and Scope
7.2 End-use Market Share Analysis, 2021 & 2030
7.3 Segment Dashboard
7.4 Global Heparin Market, by End-use, 2017 to 2030
7.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
7.5.1 Outpatient
7.5.1.1 Outpatient market, 2017 - 2030
7.5.2 Inpatient
7.5.2.1 Inpatient market, 2017 - 2030
Chapter 8 Heparin Market Segment Analysis, By Source, 2017 - 2030
8.1 Definition and Scope
8.2 Source Market Share Analysis, 2021 & 2030
8.3 Segment Dashboard
8.4 Global Heparin Market, by Source, 2017 to 2030
8.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
8.5.1 Porcine
8.5.1.1 Porcine market, 2017 - 2030
8.5.2 Bovine
8.5.2.1 Bovine market, 2017 - 2030
8.5.3 Others
8.5.3.1 Others market, 2017 - 2030
Chapter 9 Heparin Market Segment Analysis, By Region, 2017 - 2030
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2021 & 2030
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 SWOT Analysis
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 Middle East and Africa
9.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
9.6.1 North America
9.6.1.1 North America market estimates and forecast, 2017 - 2030
9.6.1.2 U.S.
9.6.1.2.1 U.S. heparin market, 2017 - 2030
9.6.1.3 Canada
9.6.1.3.1 Canada heparin market, 2017 - 2030
9.6.2 Europe
9.6.2.1 Europe heparin market, 2017 - 2030
9.6.2.2 U.K.
9.6.2.2.1 U.K. heparin market, 2017 - 2030
9.6.2.3 Germany
9.6.2.3.1 Germany heparin market, 2017 - 2030
9.6.2.4 Spain
9.6.2.4.1 Spain heparin market, 2017 - 2030
9.6.2.5 France
9.6.2.5.1 France heparin market, 2017 - 2030
9.6.2.6 Italy
9.6.2.6.1 Italy heparin market, 2017 - 2030
9.6.2.7 Russia
9.6.2.7.1 Russia heparin market, 2017 - 2030
9.6.3 Asia Pacific
9.6.3.1 Asia Pacific heparin market, 2017 - 2030
9.6.3.2 Japan
9.6.3.2.1 Japan heparin market, 2017 - 2030
9.6.3.3 China
9.6.3.3.1 China heparin market, 2017 - 2030
9.6.3.4 India
9.6.3.4.1 India heparin market, 2017 - 2030
9.6.3.5 South Korea
9.6.3.5.1 South Korea heparin market, 2017 - 2030
9.6.3.6 Australia
9.6.3.6.1 Australia heparin market, 2017 - 2030
9.6.3.7 Singapore
9.6.3.7.1 Singapore heparin market, 2017 - 2030
9.6.4 Latin America
9.6.4.1 Latin America heparin market, 2017 - 2030
9.6.4.2 Brazil
9.6.4.2.1 Brazil heparin market, 2017 - 2030
9.6.4.3 Mexico
9.6.4.3.1 Mexico heparin market, 2017 - 2030
9.6.4.4 Argentina
9.6.4.4.1 Argentina heparin market, 2017 - 2030
9.6.5 MEA
9.6.5.1 MEA heparin market, 2017 - 2030
9.6.5.2 South Africa
9.6.5.2.1 South Africa heparin market, 2017 - 2030
9.6.5.3 Saudi Arabia
9.6.5.3.1 Saudi Arabia heparin market, 2017 - 2030
9.6.5.4 UAE
9.6.5.4.1 UAE heparin market, 2017 - 2030
Chapter 10 Heparin Market - Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 Ansoff matrix
10.1.2 Heat map analysis
10.1.3 Major Deals and Strategic Alliances Analysis
10.1.3.1 Joint Ventures
10.1.3.2 Licensing Agreements
10.1.3.3 Product Launches
10.1.3.4 Conferences and Campaigns
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List of key distributors and channel partners
10.3.2 Key customers
10.4 Public Companies
10.4.1 Competitive Dashboard Analysis
10.4.2 Market Differentiators
10.5 Private Companies
10.5.1 List of key emerging companies
10.6 Company Profiles
10.6.1 GlaxoSmithKline plc (GSK)
10.6.1.1 Company overview
10.6.1.2 Financial performance
10.6.1.3 Product benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 Pfizer Inc.
10.6.2.1 Company overview
10.6.2.2 Financial performance
10.6.2.3 Product benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 LEO Pharma A/S
10.6.3.1 Company overview
10.6.3.2 Financial performance
10.6.3.3 Product benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 Sanofi
10.6.4.1 Company overview
10.6.4.2 Financial performance
10.6.4.3 Product benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 Dr. Reddy’s Laboratories Ltd.
10.6.5.1 Company overview
10.6.5.2 Financial performance
10.6.5.3 Product benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 Aspen Holdings
10.6.6.1 Company overview
10.6.6.2 Financial performance
10.6.6.3 Product benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 B. Braun Medical Inc.
10.6.7.1 Company overview
10.6.7.2 Financial performance
10.6.7.3 Product benchmarking
10.6.7.4 Strategic initiatives
10.6.8 Fresenius SE & Co. KGaA
10.6.8.1 Company overview
10.6.8.2 Financial performance
10.6.8.3 Product benchmarking
10.6.8.4 Strategic initiatives
10.6.9 Sandoz (Novartis AG)
10.6.9.1 Company overview
10.6.9.2 Financial performance
10.6.9.3 Product benchmarking
10.6.9.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers